Abstract | OBJECTIVES: SETTING: Cohort study based on the linkage of Norwegian population-based registries. PARTICIPANTS: We selected 466822 Norwegian women, aged 55-79, alive and residing in Norway as of 1 January 2004, and we followed them from 2004 to 2008. Each woman contributed person-years at risk as non-user, current user and/or past HT user. OUTCOME MEASURES: The outcome of interest was adenocarcinoma of the colorectal tract, overall, by anatomic site and stage at diagnosis. Incidence rate ratios (RRs) with 95% CIs were estimated by Poisson regression and were used to evaluate the association between HT and CRC incidence. RESULTS: During the median follow-up of 4.8 years, 138 655 (30%) women received HT and 3799 (0.8%) incident CRCs occurred. Current, but not past, use of HT was associated with a lower risk of CRC (RR 0.88; 95% CI 0.80 to 0.98). RRs for localised, regionally advanced and metastatic CRC were 1.13 (95% CI 0.91 to 1.41), 0.81 (95% CI 0.70 to 0.94) and 0.79 (95% CI 0.62 to 1.00), respectively. RRs for current use of oestrogen therapy (ET) were 0.91 (95% CI 0.80 to 1.04) while RR for current use of combined oestrogen- progestin therapy (EPT) was 0.85 (95% CI 0.70 to 1.03), as compared with no use of HT. The same figures for ET and EPT in oral formulations were 0.83 (95% CI 0.68 to 1.03) and 0.86 (95% CI 0.71 to 1.05), respectively. CONCLUSIONS: In our nationwide cohort study, HT use lowered the risk of CRC, specifically the most advanced CRC.
|
Authors | Edoardo Botteri, Nathalie C Støer, Solveig Sakshaug, Sidsel Graff-Iversen, Siri Vangen, Solveig Hofvind, Thomas de Lange, Vincenzo Bagnardi, Giske Ursin, Elisabete Weiderpass |
Journal | BMJ open
(BMJ Open)
Vol. 7
Issue 11
Pg. e017639
(Nov 15 2017)
ISSN: 2044-6055 [Electronic] England |
PMID | 29146641
(Publication Type: Journal Article)
|
Copyright | © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. |
Topics |
- Aged
- Colorectal Neoplasms
(epidemiology, prevention & control)
- Estrogen Replacement Therapy
- Female
- Follow-Up Studies
- Humans
- Incidence
- Middle Aged
- Norway
(epidemiology)
- Poisson Distribution
- Postmenopause
- Registries
- Risk Factors
|